Kymera Therapeutics (KYMR) Change in Acquisitions & Divestments (2020 - 2026)

Kymera Therapeutics (KYMR) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $133.9 million in Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $133.9 million, up 0.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $489.1 million (down 9.96% YoY), and the FY2025 annual result was $488.0 million, down 4.31% from the prior year.
• Change in Acquisitions & Divestments grew to $133.9 million in Q1 2026 per KYMR's latest filing, from $103.9 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $147.9 million in Q4 2024 and troughed at $76.1 million in Q4 2023.
• A 5-year average of $115.6 million and a median of $117.7 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments slumped 32.6% in 2023, then jumped 94.43% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $97.9 million in 2022, then decreased by 22.32% to $76.1 million in 2023, then jumped by 94.43% to $147.9 million in 2024, then decreased by 29.78% to $103.9 million in 2025, then climbed by 28.87% to $133.9 million in 2026.
• Business Quant data shows KYMR's Change in Acquisitions & Divestments at $133.9 million in Q1 2026, $103.9 million in Q4 2025, and $132.4 million in Q3 2025.